Diabetomics’s Saliva-Based COVID-19 Test Gets FDA Emergency Use Authorization

The FDA has granted Diabetomics an Emergency Use Authorization for its COVID-19 antibody test, CovAb.

The test assesses saliva samples, delivers results within 15 minutes and detects all three COVID-19 antibody classes—IgA, IgG and IgM—that are present at different stages of infection.

The highly accurate test has 97.6 percent sensitivity and 98.8 percent specificity, according to the Hillsboro, Ore.-based company.